Abstracts treatment with Peg/RBV compared with no treatment in PNALT/CHC. METHODS: Sustained viral response (SVR) was 40% for 48-week treatment in genotype 1 and 72% for 24-week treatment in genotype 2/3. Disease progression was modeled based on METAVIR scores F0 to F4, followed by cirrhosis complications and death. Mean fibrosis progression rates were derived from literature reports of biopsy series in patients with PNALT. The reference is a cohort of patients with mean age 45 years with PNALT and CHC, with distribution of fibrosis at baseline equal to that found in the trial. Quality of life and costs for each health state were based on literature estimates and on European treatment patterns. Costs in 2003 Euros and benefits were discounted at 3%. Sensitivity analyses on key clinical and economic parameters were performed. The analysis was reported from the perspective of a European National Health Service (Italian setting). RESULTS: In genotype 1, Peg/RBV compared with no treatment prolonged the time to cirrhosis by 4.8 years, increased life years (LY) by 1.4 and quality-adjusted life years (QALY) by 1 year. The incremental cost per QALY was 12,102€. In genotypes 2/3, Peg/RBV prolonged the time to cirrhosis by 8.6 years, increased LY by 2.5 and QALY by 1.8 years. The incremental cost per QALY was 1084€. Based on the distribution in the trial of 71% genotype 1, and 28% genotype 2/3, the overall CE ratio per QALY was 7419€. CONCLUSIONS: Treatment of adults with PNALT/CHC using Peg/RBV is projected to delay time until cirrhosis, increase life expectancy, and is cost-effective.
PGI6 ECONOMIC BURDEN OF GERD AND PUD IN AN EMPLOYED POPULATION
Joish VN 1 , Donaldson G 1 , Stockdale WA 1 , Oderda G 1 , Brixner DI 1 , Sasane R 2 , Joshua-Gotlib S 2 , Crawley JA 2 1 University Of Utah, Salt Lake City, UT, USA; 2 AstraZeneca LP, Wilmington, DE, USA OBJECTIVES: The objective of this study was to evaluate the differences in reported levels of absenteeism and direct medical costs between employees diagnosed with gastroesophageal reflux disease (GERD) and/or peptic ulcer disease (PUD) and a matched-cohort with neither disease. METHODS: Data were extracted from the MarketScan Research Database, a Health Insurance Portability and Accountability Act compliant database consisting of medical and prescription claims of employees linked to the absenteeism files of their employers. Employees with an ICD-9 code for GERD/PUD, and a matched cohort with neither disease, were identified from January 1, 1997 to December 31, 2000. Demographic, absenteeism, and resourceutilization variables were collected for all eligible subjects. Analysis of variance was used to test the null hypothesis that the four populations have equal means of absenteeism rates. RESULTS: In all, 6205 employees with GERD, 2702 with PUD, 3297 with both GERD and PUD, and 42,902 matched control subjects were identified. There was no significant difference between the GERD and PUD groups in health care costs, except total prescription costs that were higher in the GERD group (p < 0.001). Work-absenteeism rates appeared to increase in the expected fashion, with lowest rates in the control group and highest rates in the combined group. The magnitude of this difference was 0.3 sickness-related absence days per individual per year between the groups with and without gastrointestinal disease. For all-cause absences, the difference was higher with 1.5 absence days per year. Projections of this data to an average sized Fortune 500 company of 250,000 employees would translate to total direct costs of $312 million and indirect costs of $4.75 million per year. CONCLUSIONS: Direct medical cost and worker absenteeism, in GERD and PUD employees creates a significant burden on the employee community.
PGI7 FECAL LACTOFERRIN ASSAY FOR THE INITIAL DIAGNOSTIC APPROACH TO SYMPTOMATIC PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS: A COST-EFFECTIVENESS ANALYSIS
Ellis JJ, Parsi MA, Lashner BA Cleveland Clinic Foundation, Cleveland, OH, USA OBJECTIVES: Fecal lactoferrin (FL) is a non-invasive marker, able to distinguish between inflammatory and non-inflammatory causes of symptoms in patients with ileal pouch-anal anastomosis (IPAA). We assessed the cost-effectiveness (CE) of the FL assay as the initial screening test for the evaluation of symptomatic patients with IPAA. METHODS: The frequencies of pouchitis, irritable pouch syndrome, cuffitis, and Crohn's in symptomatic patients were estimated to be 50%, 36%, 7%, and 7% respectively. The FL assay has a sensitivity of 100% and a specificity of 85% (7 mg/ml threshold) to distinguish between inflammatory and non-inflammatory causes of symptoms. Four competing diagnostic strategies [empiric metronidazole therapy (txMTZ), initial pouch endoscopy/biopsy (testBiop), initial FL assay then MTZ when warranted (testFL + MTZ), and FL assay then pouch endoscopy/biopsy when warranted (testFL + Biop)] were modeled in a decision tree. Response rates to all therapies were based on current literature and expert opinion. Effectiveness equaled the number of days out of 30 that a patient received responsive therapy. Procedural and drug costs were estimated from the 2003 Medicare fee schedule and current average wholesale price, respectively. RESULTS: In the base case, the average cost per patient was $244 for testFL + MTZ, $251 for txMTZ, $408 for testFL + Biop, and $431 for testBiop. All competing strategies were more effective than test FL + MTZ, with incremental effectiveness ranging from 2.0 to 0.1 days at an incremental cost ranging from $8 to $1263. The incremental CE ratio for txMTZ and testFL + MTZ of only $8 does not reflect unnecessary antibiotic exposure resulting in delayed diagnosis, adverse effects, antimicrobial resistance, or patient preference for the 50% relative decrease in invasive endoscopic procedures. Results were robust in multivariate sensitivity analyses. CONCLU-SIONS: FL measurement prior to treatment with MTZ is a less costly strategy with only a marginal decrease in effectiveness when compared to empiric antibiotic therapy and other diagnostic strategies.
PGI8 A PHARMACOECONOMIC ASSESSMENT OF THE BENEFITS AND COSTS OF MANAGING IMMUNOSUPPRESSION IN POST-LIVER TRANSPLANT PATIENTS: A UNIVERSITY HOSPITAL PERSPECTIVE
Stolpman NM 1 ,Valuck RJ 2 , Lezotte D 2 , Malone DC 3 , Glazner J 2 , Everson GT 2 1 University of Colorado Hospital, Denver, CO, USA; 2 University of Colorado Health Sciences Center, Denver, CO, USA; 3 University of Arizona, Tucson, AZ, USA OBJECTIVES: The overall aim of this investigation was to determine the best use of post-transplant immunosuppression therapies, in terms of clinical and economic outcomes, for the liver transplant population at the University of Colorado Hospital (UCH), regardless of expected reimbursement. METHODS: Patients were sequentially assigned to either tacrolimus (FK) or emulsified cyclosporine (CYA) with or without mycophenolate
